Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)
Launched by BOSTON CHILDREN'S HOSPITAL · Apr 26, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq) is a clinical trial focused on understanding how genetics play a role in hereditary spastic paraplegia (HSP) and related disorders. HSP is a group of more than 80 inherited diseases that cause progressive stiffness and weakness in the legs. Many children with this condition experience vague symptoms at first, leading to delays in diagnosis. The researchers aim to identify specific genetic factors that contribute to HSP, which could eventually lead to better treatments tailored to different types of the condition.
To participate in this study, individuals aged 30 and older who have been clinically diagnosed with progressive spasticity may be eligible. Participants will undergo genetic testing to help researchers learn more about the genetic causes of HSP. This study is currently recruiting and welcomes participants of all genders. By taking part in this research, individuals can contribute to a greater understanding of HSP, which may improve diagnosis and treatment options in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis of progressive spasticity
About Boston Children's Hospital
Boston Children's Hospital is a leading pediatric healthcare institution renowned for its commitment to advancing child health through innovative research and exceptional clinical care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise in pediatric medicine to conduct rigorous and ethically sound research studies aimed at improving treatment options and outcomes for children. With a collaborative approach that integrates cutting-edge technology and multidisciplinary teams, Boston Children's Hospital is dedicated to translating scientific discoveries into practical applications that enhance the well-being of young patients and their families.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Darius Ebrahimi-Fakhari, MD, PhD
Principal Investigator
Boston Children's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials